지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 638 - 644 (7page)
이용수
초록· 키워드
오류제보하기
Purpose There is no regimen that is strongly recommended for more than second-line treatment.
We investigated the efficacy and safety of platinum/vinorelbine as more than second-linetreatment.
Materials and MethodsWe selected patients with advanced non-small cell lung cancer (NSCLC) who received treatmentwith platinum/vinorelbine at Chungnam National University Hospital from August2001 to December 2013. The primary end point was the response rate, and secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity.
ResultsThirty-five patients were enrolled. Response rate was 22.9% (complete response, 0 patients[0%]; partial response, eight patients [22.9%]; stable disease, 10 patients [28.6%]; progressivedisease, 14 patients [40.0%]). A significantly higher response rate was observed forpatients who had responded to previous chemotherapy than for those who did not (34.8%[8/23] vs. 0% [0/12], p=0.020). The median PFS was 4 months (range, 1 to 21 months).
Patients with adenocarcinoma and non-smokers had a significantly longer PFS than patientswith non-adenocarcinoma and smokers (5 months vs. 2 months, p=0.007; 4.5 months vs.
2 months, p=0.046, respectively). The median OS was 10 months (range, 1 to 41 months).
Patients with good performance status and non-smokers had a significantly longer OS thanpatients with poor performance status and smokers (14 months vs. 4 months, p=0.02;18.5 months vs. 6 months, p=0.049, respectively). The main serious adverse event (grade3 or 4) was neutropenia (15 events, 13.3%) in a total of 113 cycles.
ConclusionPlatinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicitywas tolerable, in patients with advanced NSCLC.
목차
등록된 정보가 없습니다.
참고문헌 (16)
참고문헌 신청
Asahina H / 2012 / Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer / Clin Lung Cancer 13 : 39 ~ 43
Azzoli CG / 2011 / 2011 Focused update of 2009 american society of clinical oncology clinical practice guideline update on chemotherapy for stage iv non-small-cell lung canc
Chang MH / 2010 / The efficacy of pemetrexed as a third-or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small ce
Fossella F / 2003 / Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung canc
Girard N / 2009 / Third-line chemotherapy in advanced non-small cell lung cancer : identifying the candidates for routine practice / J Thorac Oncol 4 : 1544 ~ 1549
Azzoli CG / 2011 / 2011 Focused update of 2009 american society of clinical oncology clinical practice guideline update on chemotherapy for stage iv non-small-cell lung canc
Chang MH / 2010 / The efficacy of pemetrexed as a third-or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small ce
Fossella F / 2003 / Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung canc
Girard N / 2009 / Third-line chemotherapy in advanced non-small cell lung cancer : identifying the candidates for routine practice / J Thorac Oncol 4 : 1544 ~ 1549
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Lung Cancer in Women, a Different Disease: Survival Differences by Sex in Turkey
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy
Cancer Research and Treatment
2016 .01
-
Active Treatment Improves Overall Survival in Extremely Older Non-Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study
Cancer Research and Treatment
2021 .01
-
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Cancer Research and Treatment
2022 .04
-
Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Estimating the Survival of Patients With Lung Cancer: What Is the Best Statistical Model?
예방의학회지
2019 .01
-
Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea
Cancer Research and Treatment
2020 .01
-
ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2017 .07
-
Analyses of Multiple Factors for Determination of "Selected Patients" Who Should Receive Rechallenge Treatment in Metastatic Colorectal Cancer: a Retrospective Study from Turkey
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Atezolizumab in Patients with Pretreated Urothelial Cancer: A Korean Single-Center, Retrospective Study
Cancer Research and Treatment
2019 .01
-
Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
Tuberculosis and Respiratory Diseases
2018 .01
-
Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Cancer Research and Treatment
2022 .04
-
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
Cancer Research and Treatment
2015 .01
-
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Cancer Research and Treatment
2020 .01
-
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2016 .01
-
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
Cancer Research and Treatment
2017 .07
-
The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma
Tuberculosis and Respiratory Diseases
2019 .01
-
Prognostic influence of an early time to chemotherapy following primary cytoreductive surgery for advanced epithelial ovarian cancer
Journal of Gynecologic Oncology
2022 .11
이 논문의 저자 정보
최근 본 자료
댓글(0)
0